Belvedere Trading
CYTK icon

Belvedere Trading’s Cytokinetics CYTK Stock Holding History

Belvedere Trading’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,469
Closed -$209K – 745
2024
Q1 		$243K Buy
+3,469
New +$268K ﹤0.01% 287
2023
Q4 		– Sell
-2,302
Closed -$83.4K – 849
2023
Q3 		$67.8K Buy
+2,302
New +$76.7K ﹤0.01% 387

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Belvedere Trading's CYTK Position: Q2 2024 in Review

Belvedere Trading sold out of Cytokinetics (CYTK) in Q2 2024, closing a stake of 3,469 shares — an estimated $209K sold.

Belvedere Trading first reported a position in CYTK in Q3 2023 and held it in 2 quarters. The position peaked at $243K in Q1 2024. 343 funds tracked by Wall St. Rank hold CYTK as of Q2 2024.

  • Belvedere Trading reported no remaining Cytokinetics position as of Q2 2024 after selling out during the quarter.
  • Belvedere Trading sold 3,469 Cytokinetics shares in Q2 2024, an estimated $209K.
  • Belvedere Trading first reported a position in Cytokinetics in Q3 2023 and held it in 2 quarters.
  • Belvedere Trading's Cytokinetics position peaked at $243K in Q1 2024.
  • 343 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2024.

Based on Belvedere Trading's 13F filing for Q2 2024, filed 9 Aug 2024.